Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%
Enterprise value$3.53B+275%
P/S15.4×+7.5×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive)?
Arcus Biosciences (RCUS) reported total cash, cash equivalents, and restricted cash (inclusive) of $204M in Q1 2026.
How has Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive) increased by 4.6% year-over-year, from $195M to $204M.
What is the long-term trend for Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive)?
Over 4 years (2021 to 2025), Arcus Biosciences's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 10.5% compound annual growth rate (CAGR), from $151M to $225M.